Savara (NASDAQ:SVRA) Sees Unusually-High Trading Volume – Should You Buy?

Shares of Savara Inc. (NASDAQ:SVRA) saw unusually-strong trading volume on Wednesday . Approximately 993,000 shares were traded during mid-day trading, a decline of 38% from the previous session’s volume of 1,606,575 shares.The stock last traded at $5.77 and had previously closed at $5.84.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on SVRA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Friday. Oppenheimer started coverage on Savara in a research note on Friday, April 24th. They issued an “outperform” rating and a $11.00 target price for the company. Finally, Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Savara presently has an average rating of “Moderate Buy” and a consensus price target of $10.14.

Savara Price Performance

The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47. The firm has a market capitalization of $1.17 billion, a P/E ratio of -10.22 and a beta of 0.24. The company’s 50 day moving average price is $5.51 and its 200 day moving average price is $5.53.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). As a group, sell-side analysts anticipate that Savara Inc. will post -0.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Savara

Several hedge funds and other institutional investors have recently made changes to their positions in SVRA. Prudential Financial Inc. bought a new stake in shares of Savara during the second quarter worth $30,000. BNP Paribas Financial Markets boosted its holdings in Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after acquiring an additional 4,626 shares during the last quarter. Brevan Howard Capital Management LP acquired a new stake in Savara in the second quarter worth about $33,000. Russell Investments Group Ltd. increased its position in Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after purchasing an additional 9,463 shares during the period. Finally, CIBC Bancorp USA Inc. bought a new stake in Savara during the 3rd quarter worth about $44,000. 87.93% of the stock is owned by institutional investors and hedge funds.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.